remove_red_eye 516 Views
#Business And Medicine #Pathology and Lab Medicine #Pharmacist #Transplantation
A new report published October 30, 2019 in the New England Journal of Medicine describes two patients in whom extended-spectrum beta-lactamase (ESBL)–producing Escherichia coli bacteremia occurred after they had undergone FMT in two independent clinical trials; both cases were linked to the same stool donor by means of genomic sequencing. One of the patients died. The report further says that enhanced donor screening to limit the transmission of microorganisms that could lead to adverse infectious events and continued vigilance to define the benefits and risks of FMT across different patient populations are warranted.